

Table 19.29
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2008-2014

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	181,324	70.7 (70.4 , 70.9)	90.4 (89.7 , 91.1)	78.1 (77.7 , 78.4)	60.6 (60.1 , 61.1)			
1 Hodgkin Lymphoma	14,692	86.6 (85.9 , 87.3)	96.7 (95.5 , 97.5)	90.0 (89.3 , 90.7)	58.3 (55.3 , 61.2)			
2 Non-Hodgkin lymphoma	162,599	69.6 (69.3 , 69.9)	88.8 (88.0 , 89.6)	76.5 (76.2 , 76.9)	61.3 (60.8 , 61.8)			
2(a) Non-Hodgkin lymphoma, B-cell	150,729	70.0 (69.6 , 70.3)	89.4 (88.5 , 90.3)	77.2 (76.8 , 77.6)	61.8 (61.3 , 62.4)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	8,367	68.5 (67.3 , 69.6)	88.9 (87.8 , 89.9)	40.0 (37.6 , 42.3)	18.2 (14.7 , 22.1)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	134,401	70.2 (69.9 , 70.5)	92.1 (90.1 , 93.7)	78.8 (78.4 , 79.2)	62.3 (61.7 , 62.8)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	32,466	80.2 (79.5 , 80.9)	- (- , -)	88.0 (87.2 , 88.8)	74.7 (73.6 , 75.8)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	28,401	83.2 (82.5 , 84.0)	- (- , -)	91.1 (90.3 , 91.9)	77.9 (76.7 , 79.0)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	89	54.7 (40.3 , 67.0)	- (- , -)	60.5 (36.1 , 78.0)	46.4 (28.8 , 62.3)			
2(a) 2.1.3. Mantle-cell lymphoma	3,976	58.9 (56.7 , 61.0)	- (- , -)	68.7 (65.8 , 71.4)	50.9 (47.7 , 54.0)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,968	82.1 (79.6 , 84.4)	- (- , -)	89.2 (86.2 , 91.6)	78.0 (74.4 , 81.2)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,329	79.0 (75.1 , 82.4)	- (- , -)	84.9 (79.9 , 88.7)	75.6 (70.1 , 80.3)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,639	84.6 (81.1 , 87.5)	- (- , -)	92.8 (88.7 , 95.5)	80.0 (74.8 , 84.1)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	34,659	62.8 (62.1 , 63.4)	90.6 (87.2 , 93.2)	72.4 (71.6 , 73.2)	53.0 (52.0 , 54.1)			
2(a) 2.3.1. DLBCL, NOS ^c	34,153	62.5 (61.9 , 63.2)	90.8 (87.3 , 93.4)	72.2 (71.3 , 73.0)	53.0 (52.0 , 54.1)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	65	47.8 (33.5 , 60.7)	- (- , -)	49.1 (31.4 , 64.7)	45.1 (23.1 , 64.9)			
2(a) 2.3.3. Primary effusion lymphoma	46	33.7 (17.7 , 50.4)	- (- , -)	33.9 (16.4 , 52.4)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	395	88.0 (83.6 , 91.3)	87.0 (64.6 , 95.6)	90.1 (85.6 , 93.3)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	2,192	63.4 (61.1 , 65.6)	91.7 (88.6 , 93.9)	60.0 (57.0 , 62.8)	38.6 (33.0 , 44.2)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	9,805	90.4 (89.2 , 91.4)	98.7 (90.7 , 99.8)	93.5 (92.4 , 94.5)	87.1 (85.0 , 88.9)			
2(a) 2.5.1. Splenic MZL	849	86.9 (82.4 , 90.3)	- (- , -)	88.1 (82.7 , 91.8)	85.3 (79.7 , 89.5)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	6,024	94.2 (92.8 , 95.4)	98.0 (86.6 , 99.7)	95.6 (94.3 , 96.6)	92.4 (89.8 , 94.4)			
2(a) 2.5.3. Nodal MZL	2,932	83.5 (81.2 , 85.6)	- (- , -)	90.0 (87.6 , 92.0)	77.9 (74.1 , 81.2)			
2(a) 2.6. Follicular lymphoma	17,737	87.8 (87.0 , 88.6)	97.1 (80.0 , 99.6)	92.4 (91.6 , 93.1)	81.8 (80.1 , 83.2)			
2(a) 2.7. Hairy-cell leukemia	1,530	93.4 (90.8 , 95.2)	- (- , -)	97.0 (94.7 , 98.4)	83.7 (76.4 , 88.9)			
2(a) 2.8. Plasma cell neoplasms	33,021	50.7 (49.9 , 51.4)	- (- , -)	62.6 (61.5 , 63.6)	41.4 (40.4 , 42.4)			
2(a) 2.8.1. Plasmacytoma	2,016	69.5 (66.6 , 72.2)	- (- , -)	79.7 (76.4 , 82.6)	55.9 (50.8 , 60.6)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	31,005	49.4 (48.7 , 50.2)	- (- , -)	61.1 (60.0 , 62.2)	40.7 (39.6 , 41.7)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	7,961	67.7 (66.2 , 69.2)	89.9 (78.9 , 95.4)	76.6 (74.6 , 78.4)	61.8 (59.5 , 64.0)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2008-2014

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	11,126	65.5 (64.4 , 66.6)	85.9 (83.7 , 87.8)	69.6 (68.3 , 70.9)	51.0 (48.7 , 53.2)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	288	64.8 (58.8 , 70.2)	90.4 (83.9 , 94.3)	46.9 (37.8 , 55.5)	- (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	10,815	65.6 (64.4 , 66.7)	85.2 (82.8 , 87.4)	70.3 (68.9 , 71.6)	51.4 (49.1 , 53.6)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,728	89.9 (87.8 , 91.6)	100.0 (- , -)	92.5 (90.5 , 94.1)	83.5 (78.3 , 87.5)			
2(b) 2.1.1. Mycosis fungoides	2,640	91.5 (89.4 , 93.2)	100.0 (- , -)	93.5 (91.5 , 95.0)	86.4 (81.0 , 90.3)			
2(b) 2.1.2. Sezary syndrome	88	38.7 (24.0 , 53.2)	- (- , -)	40.3 (19.7 , 60.2)	37.0 (17.8 , 56.4)			
2(b) 2.2. Peripheral T-cell lymphoma	5,815	58.2 (56.6 , 59.7)	85.7 (80.6 , 89.6)	66.4 (64.5 , 68.2)	43.5 (40.8 , 46.3)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	2,054	39.5 (36.9 , 42.1)	59.1 (41.5 , 73.0)	50.0 (46.5 , 53.4)	26.7 (23.0 , 30.6)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	775	38.8 (34.6 , 43.0)	- (- , -)	47.6 (41.4 , 53.6)	31.7 (26.1 , 37.5)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	83	91.0 (77.8 , 96.5)	- (- , -)	88.6 (71.8 , 95.7)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,130	65.3 (61.9 , 68.5)	90.0 (83.8 , 93.9)	69.6 (65.6 , 73.3)	39.6 (31.6 , 47.6)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	62	26.1 (14.0 , 40.0)	- (- , -)	24.3 (11.1 , 40.4)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	63	8.6 (2.6 , 19.2)	- (- , -)	8.6 (1.5 , 23.5)	9.3 (1.7 , 24.7)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	1,143	86.0 (82.8 , 88.8)	96.6 (77.8 , 99.5)	89.6 (86.1 , 92.2)	78.6 (72.4 , 83.6)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	505	88.0 (82.7 , 91.8)	- (- , -)	93.1 (88.3 , 96.0)	78.5 (65.8 , 86.9)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	1,572	63.6 (60.7 , 66.3)	83.7 (80.6 , 86.4)	49.2 (44.5 , 53.8)	18.7 (11.9 , 26.9)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	463	42.8 (37.5 , 48.0)	- (- , -)	43.0 (37.0 , 48.9)	39.0 (27.4 , 50.5)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	56	67.6 (51.1 , 79.6)	- (- , -)	74.6 (54.2 , 86.9)	56.3 (29.4 , 76.4)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	181	14.0 (8.0 , 21.6)	- (- , -)	22.5 (12.9 , 33.6)	3.1 (0.3 , 12.8)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	744	60.8 (56.7 , 64.7)	89.4 (83.2 , 93.4)	59.1 (52.7 , 65.0)	47.1 (39.8 , 54.0)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	315	63.7 (57.9 , 69.0)	89.2 (82.9 , 93.3)	47.0 (36.2 , 57.1)	22.6 (12.5 , 34.6)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	28	48.1 (28.3 , 65.3)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	401	59.2 (53.2 , 64.8)	- (- , -)	65.6 (57.4 , 72.5)	53.6 (44.7 , 61.6)			
2(*) 1. Total precursor lymphoma/leukemia ^d	8,970	68.2 (67.1 , 69.3)	89.0 (88.0 , 89.9)	40.8 (38.6 , 42.9)	18.4 (15.1 , 22.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	206	76.7 (68.8 , 82.9)	- (- , -)	84.3 (74.8 , 90.4)	62.6 (47.9 , 74.2)			
4 Lymphoid neoplasm, NOS ^c	3,827	50.4 (48.4 , 52.4)	84.6 (75.6 , 90.5)	66.3 (63.4 , 69.0)	38.7 (35.9 , 41.4)			

Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.